ClarityIQ technology
ClarityIQ masthead image

Clinically proven

Azurion with ClarityIQ technology

    What is ClarityIQ technology?

     

    Our imaging technology ClarityIQ, combines advanced, real-time image noise reduction algorithms with state-of-the-art hardware. Together, they form a flexible digital imaging pipeline designed to perform individual image processing algorithms more efficiently. This unlocks superb visualization and significant dose reduction capabilities for healthcare facilities. ClarityIQ is available as an option on Azurion systems.

    Key benefits of ClarityIQ technology

    • Significantly lower patient dose at equivalent image quality 
    • Proven reduction in staff radiation exposure
    • Fast – no noticeable delay between acquisition and display

    Philips image-guided therapy system scores high in multi-vendor study.a This study identifies differences between image-guided therapy systems from different vendors. It may pave a path for standardization in radiation dose usage and acceptable image quality for similar procedures.

    Clinically proven outcomes across interventional areas

     

    ClarityIQ is clinically proven to deliver significantly lower dose – based on 37 multiple peer-reviewed clinical studies with over
    19.000 patients1-38,b-d

    Select an area of interest and discover more about ClarityIQ study findings in this area.

    Doctors checking data

    The next leap in lab integration

     

    When Azurion was introduced, we marked a pivotal moment in image-guided therapy. Its highly intuitive usability and unique innovations help clinicians to optimize interventional lab performance and provide superior care. Reaching the landmark two millionth procedure in just over 3.5 years*, this image-guided therapy platform keeps advancing. Azurion’s next leap in lab integration and 3D imaging gives you control over an array of compatible applications from a single touch screen interface at table side.

    *More than two million procedures have been performed on Philips Azurion based on Philips internal case and procedure data. The two millionth case was performed in August 2020 and was estimated based on the same data.

    *

    Contact information

    * This field is mandatory

    *
    *
    *
    *
    *
    *
    *
    *
    *

    By specifying your reason for contact we will be able to provide you with a better service.

    We work with partners and distributors who may contact you about this Philips product on our behalf.

    *
    *

    Final CEE consent

    You are about to visit a Philips global content page

    Continue

    You are about to visit a Philips global content page

    Continue

    Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

    You are entering a Philips Healthcare Australia website
    Please select the checkbox

    The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

    By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.